Colorectal Clinical Trials

1,087 recruitingLast updated: May 21, 2026

There are 1,087 actively recruiting colorectal clinical trials across 63 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Colorectal Trials at a Glance

1,087 actively recruiting trials for colorectal are listed on ClinicalTrialsFinder across 6 cities in 63 countries. The largest study group is Phase 2 with 323 trials, with the heaviest enrollment activity in Houston, New York, and Los Angeles. Lead sponsors running colorectal studies include Fudan University, Sun Yat-sen University, and M.D. Anderson Cancer Center.

About Colorectal Clinical Trials

Looking for clinical trials for Colorectal? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,087 trials

Recruiting
Phase 4

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Colorectal, Cancer
Takeda78 enrolled45 locationsNCT06562543
Recruiting
Not Applicable

PRIORITY-CONNECT 2 Trial

Colorectal, CancerColorectal Neoplasms
Surgical Outcomes Research Centre (SOuRCe)564 enrolled31 locationsNCT06976710
Recruiting
Phase 1

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal, CancerMinimal Residual Disease
M.D. Anderson Cancer Center42 enrolled1 locationNCT06358430
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled10 locationsNCT07540572
Recruiting
Phase 2

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer
M.D. Anderson Cancer Center33 enrolled1 locationNCT06369259
Recruiting
Phase 2

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
M.D. Anderson Cancer Center90 enrolled1 locationNCT06959550
Recruiting
Not Applicable

Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities

Colorectal, CancerPeripheral Neuropathy
Vejle Hospital120 enrolled4 locationsNCT05404230
Recruiting

Anastomotic Leakage After Colorectal Surgery.

Colorectal, CancerAnastomotic LeakDiverticulitis
Minia University430 enrolled1 locationNCT07144683
Recruiting
Phase 1

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Advanced/Metastatic Colorectal Adenocarcinoma
Bayer130 enrolled21 locationsNCT07535112
Recruiting
Phase 2

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Colorectal, Cancer
Ono Pharmaceutical Co., Ltd.144 enrolled33 locationsNCT06948448
Recruiting
Phase 1Phase 2

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic Ductal AdenocarcinomaSolid Tumor, Adult
Crossignal Therapeutics, Inc.78 enrolled1 locationNCT06598007
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Colorectal, CancerNon-small Cell Lung CancerSolid Tumor+1 more
Astellas Pharma Inc364 enrolled20 locationsNCT07094204
Recruiting
Phase 1Phase 2

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Gastric CancersColorectal, CancerPancreatic Cancer+1 more
Bold Therapeutics, Inc.220 enrolled24 locationsNCT04421820
Recruiting
Phase 2

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Metastatic Colorectal CancerAdvanced Colorectal Cancer
Riboscience, LLC.150 enrolled5 locationsNCT06824064
Recruiting
Not Applicable

BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Colorectal AdenomaColorectal Cancer Prevention
Massachusetts General Hospital40 enrolled1 locationNCT07162337
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal, Cancer
AbbVie140 enrolled45 locationsNCT07023289
Recruiting
Not Applicable

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Appendiceal AdenocarcinomaColorectal
M.D. Anderson Cancer Center48 enrolled1 locationNCT05947838
Recruiting
Phase 2Phase 3

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

Colorectal (Colon or Rectal) Cancer
RemeGen Co., Ltd.80 enrolled19 locationsNCT07462143